ClinicalTrials.gg

Program

sacituzumab tirumotecan

Also written as “Sacituzumab tirumotecan”, “SKB264” and “Sacituzumab Tirumotecan”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Breast Neoplasms · Urinary Bladder Neoplasms · Esophageal Neoplasms, led by 4 companies.

Furthest: phase 3, since Oct 3, 202350 company-led studies, 48 open or runningLicense: Kelun-Biotech → MerckNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck2928 open or runningphase 3since Oct 3, 2023Apr 1, 2022May 10, 2027phase 3 · NCT06074588
Sichuan Kelun Pharmaceutical1716 open or runningphase 3since Apr 15, 2022Apr 15, 2022Nov 2026phase 3 · NCT06448312
Klus Pharma33 open or runningphase 2since Oct 29, 2019Oct 29, 2019Nov 30, 2027phase 2 · NCT05642780
Convalife (Shanghai)11 open or runningphase 2since Aug 22, 2025Aug 22, 2025Aug 12, 2028phase 2 · NCT07157956
  • Named in Merck’s own pipeline as sacituzumab tirumotecan (MK-2870), phase 4, as of Nov 2, 2026 (source).

Also a collaborator on its studies: Daiichi Sankyo and Myriad Genetics.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

How Klus Pharma and Convalife (Shanghai) relate to it is not in the registry or these sources.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 35 studies since Oct 29, 2019.

  1. May 4, 2025Phase 3 study in Breast NeoplasmsMerck · NCT06966700 · 2,400 planned · United States, Argentina, Australia and more
  2. Jun 19, 2025Phase 3 study in Breast NeoplasmsSichuan Kelun Pharmaceutical · NCT07071337 · 430 planned · China
  3. Aug 22, 2025Convalife (Shanghai)’s first study: phase 2 study in Advanced Solid TumorNew to Convalife (Shanghai)Convalife (Shanghai) · NCT07157956 · 318 planned · China
  4. Oct 10, 2025Phase 3 study in Uterine Cervical NeoplasmsMerck · NCT07216703 · 1,023 planned · United States, Argentina, Austria and more
  5. Nov 20, 2025Phase 2 study in NeoplasmsMerck · NCT07252739 · 140 planned · United States, Chile, China and more
  6. Dec 11, 20253 phase 2 studiesSichuan Kelun Pharmaceutical · NCT07329322, NCT07324629, NCT07341100
  7. Jan 2, 2026Phase 3 study in Ovarian NeoplasmsMerck · NCT07318558 · 900 planned · United States, Argentina, Australia and more
  8. Feb 10, 2026Phase 3 study in Urinary Bladder NeoplasmsMerck · NCT07419295 · 590 planned · United States, Argentina, Australia and more
  9. May 7, 2026Phase 2 study in Advanced Solid TumorsSichuan Kelun Pharmaceutical · NCT07586943 · 530 planned · China
  10. Jul 3, 2026Phase 2 study in NSCLCSichuan Kelun Pharmaceutical · NCT07697586 · 206 planned · China
  11. Sep 15, 2026Phase 3 study in Urinary Bladder NeoplasmsMerck · NCT07829783 · 400 planned · Taiwan, Ukraine
  12. Sep 28, 2026Phase 2 study in Non-Squamous Non-Small Cell Lung CancerSichuan Kelun Pharmaceutical · NCT07854509 · 110 planned
  13. Oct 21, 2026Primary completion moved from 2026-07 to 2027-04Date moved laterphase 3 · +9 months · NCT06279364
  14. Oct 26, 2026Phase 2 study in Metastatic Castration-resistant Prostate CancerMerck · NCT07908524 · 290 planned

Ahead

  1. Nov 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungSichuan Kelun Pharmaceutical · NCT06448312
  2. Dec 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungSichuan Kelun Pharmaceutical · NCT06711900
  3. Dec 30, 2026Primary completion: phase 2 study in Selected Subjects With Advanced Solid TumorsSichuan Kelun Pharmaceutical · NCT05631262
  4. Dec 31, 2026Primary completion: phase 3 study in Breast NeoplasmsSichuan Kelun Pharmaceutical · NCT06081959

TargetBeta

“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugate…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) ”NCIt, by rule

Other programs on TACSTD2

ProgramCompanyFurthest phaseStudies
sacituzumab govitecanruleGilead Sciencesphase 430
datopotamab deruxtecanruleAstraZenecaphase 328
JSKN016ruleAlphamab Oncologyphase 35
Anti-TROP2 Antibody-drug Conjugate ESG401ruleQilu Pharmaceuticalphase 33
Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036CruleMinghui Pharmaceuticalphase 23
sacituzumab drozuntecanruledualitybio-incphase 22
Anti-TROP-2 Antibody-drug Conjugate OBI-902ruleobi-pharma-incphase 21
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998ruleAstellas Pharmaphase 21
JSKN016HCruleAlphamab Oncologyphase 11
KH815ruleChengdu Kanghong Pharmaceutical Groupphase 11

Studies

All 50 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07908524Metastatic Castration-resistant Prostate Cancer2Not yet recruitingMerckJun 29, 2032290
NCT07854509Non-Squamous Non-Small Cell Lung Cancer2Not yet recruitingSichuan Kelun PharmaceuticalDec 30, 2027110
NCT07829783Urinary Bladder Neoplasms · Taiwan, Ukraine3RecruitingMerckNov 17, 2031400
NCT07697586NSCLC · China2RecruitingSichuan Kelun PharmaceuticalAug 2028206
NCT07586943Advanced Solid Tumors · China2RecruitingSichuan Kelun PharmaceuticalDec 2029530
NCT07419295Urinary Bladder Neoplasms · United States, Argentina, Australia and more3RecruitingMerckJul 27, 2029590
NCT07318558Ovarian Neoplasms · United States, Argentina, Australia and more3RecruitingMerckFeb 25, 2033900
NCT07341100Carcinoma, Ovarian Epithelial · China2Active, not recruitingSichuan Kelun PharmaceuticalJan 202820
NCT07329322Carcinoma, Non-Small-Cell Lung · China2RecruitingSichuan Kelun PharmaceuticalAug 31, 202730
NCT07324629Thymoma · China2RecruitingSichuan Kelun PharmaceuticalApr 202830
NCT07252739Neoplasms · United States, Chile, China and more2RecruitingMerckNov 15, 2029140
NCT07216703Uterine Cervical Neoplasms · United States, Argentina, Austria and more3RecruitingMerckOct 29, 20311,023
NCT07157956Advanced Solid Tumor · China2Not yet recruitingConvalife (Shanghai)Aug 12, 2028318
NCT07071337Breast Neoplasms · China3RecruitingSichuan Kelun PharmaceuticalJul 2027430
NCT06966700Breast Neoplasms · United States, Argentina, Australia and more3RecruitingMerckMar 23, 20332,400
NCT06952504Endometrial Neoplasms · United States, Argentina, Australia and more3RecruitingMerckMay 24, 20321,123
NCT06841354Triple Negative Breast Neoplasms · United States, Argentina, Australia and more3RecruitingMerckMay 18, 20301,000
NCT06824467Ovarian Neoplasms · United States, Argentina, Australia and more3RecruitingMerckApr 27, 2029770
NCT06788912Lung Neoplasms · United States, Chile, Greece and more2Active, not recruitingMerckFeb 6, 203260
NCT06780111Esophageal Squamous Cell Carcinoma · United States, Brazil, Chile and more2RecruitingMerckJan 4, 2032298
NCT06711900Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingSichuan Kelun PharmaceuticalDec 2026432
NCT06670196Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingSichuan Kelun PharmaceuticalMay 2027420
NCT06637423Non-Muscle Invasive Bladder Neoplasms · United States, Canada, France and more2CompletedMerckSep 30, 202635
NCT06483334Carcinoma, Transitional Cell · United States, Canada, France and more2Active, not recruitingMerckMar 31, 202838
NCT06469944Esophageal Neoplasms · United States, Brazil, Chile and more2RecruitingMerckSep 12, 2029160
NCT06459180Uterine Cervical Neoplasms · United States, Argentina, Australia and more3Active, not recruitingMerckJun 15, 2028686
NCT06448312Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingSichuan Kelun PharmaceuticalNov 2026406
NCT06445972Esophageal Neoplasms · United States, Brazil, Chile and more2RecruitingMerckMay 9, 2028210
NCT06428409Colorectal Neoplasms · United States, Australia, Canada and more2RecruitingMerckOct 16, 2029220
NCT06422143Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more3RecruitingMerckJan 12, 2029851
NCT06393374Triple Negative Breast Neoplasms · United States, Argentina, Australia and more3RecruitingMerckDec 16, 20301,530
NCT06356311Adenocarcinoma Of Esophagus · United States, Belgium, Brazil and more3Active, not recruitingMerckOct 19, 2026473
NCT06312137Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingMerckFeb 21, 2034780
NCT06312176Breast Neoplasms · United States, Argentina, Australia and more3RecruitingMerckJul 11, 20271,200
NCT06305754Carcinoma, Non-Small-Cell Lung · United States, Argentina, Canada and more3Active, not recruitingMerckAug 17, 2028550
NCT06279364Triple Negative Breast Neoplasms · China3Active, not recruitingSichuan Kelun PharmaceuticalApr 2027537
NCT06170788Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingMerckJan 25, 2028614
NCT06132958Endometrial Neoplasms · United States, Argentina, Australia and more3Active, not recruitingMerckJan 10, 2028710
NCT06081959Breast Neoplasms · China3RecruitingSichuan Kelun PharmaceuticalDec 31, 2026376
NCT06074588Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more3Active, not recruitingMerckMay 10, 2027556
NCT06049212Carcinoma, Non-Small-Cell Lung · Japan1Active, not recruitingMerckDec 31, 202730
NCT05870319Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingSichuan Kelun PharmaceuticalJul 11, 2024376
NCT05816252Carcinoma, Non-Small-Cell Lung · China, Georgia, Romania and more2Active, not recruitingKlus PharmaAug 31, 2026356
NCT05642780Solid Tumor · United States, Australia, Belgium and more2Active, not recruitingKlus PharmaNov 30, 2027240
NCT05631262Selected Subjects With Advanced Solid Tumors · China2Active, not recruitingSichuan Kelun PharmaceuticalDec 30, 2026321
NCT05445908Triple Negative Breast Neoplasms · China2CompletedSichuan Kelun PharmaceuticalJul 31, 2026184
NCT05351788Carcinoma, Non-Small-Cell Lung · China2RecruitingSichuan Kelun PharmaceuticalAug 2026110
NCT05347134Triple Negative Breast Neoplasms · China3Active, not recruitingSichuan Kelun PharmaceuticalNov 30, 2023254
NCT05319730Esophageal Squamous Cell Carcinoma · United States, Brazil, Chile and more2RecruitingMerckJun 11, 2027230
NCT04152499Carcinoma, Ovarian Epithelial · United States, Canada, Chile and more2Active, not recruitingKlus PharmaNov 30, 20251,410

How it is read

Names in the registry

  • “Sacituzumab tirumotecan”, 22 entries
  • “SKB264”, 15 entries
  • “Sacituzumab Tirumotecan”, 5 entries
  • “SKB264+SKB118”, 2 entries
  • “Sac-TMT”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.